0A6I Stock Chart & Stats
$0.37
$0.02(4.22%)
At close: 4:00 PM EDT
$0.37
$0.02(4.22%)
Day’s Range― - ―
52-Week Range$0.28 - $6.20
Previous CloseN/A
Volume1.25K
Average Volume (3M)16.74K
Market Cap
$8.71M
Enterprise Value-$3.19
Total Cash (Recent Filing)$9.81M
Total Debt (Recent Filing)$302.59K
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Nov 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding21,765,478
10 Day Avg. Volume7,008
30 Day Avg. Volume16,738
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.50Price Target Upside305.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Government-funded Biodefense FocusSoligenix’s strategic focus on biodefense and public-health preparedness secures access to non-dilutive grants and government contracts. This creates a durable funding channel and elongated program timelines that can underwrite R&D spending independent of commercial sales, stabilizing operations while clinical development proceeds.
Materially Reduced LeverageThe sharp reduction in debt markedly lowers solvency pressure and interest obligations, improving financial flexibility. Lower leverage strengthens the company’s ability to pursue strategic options or absorb further trial setbacks without immediate creditor distress, extending runway for clinical and strategic pivots.
Equity-market Access Via ATM ProgramExpanded at-the-market issuance capacity provides an ongoing, opportunistic capital source to support operations, trial wind-downs, or pivots without negotiating bespoke financing. While dilutive, this market access is a durable liquidity tool that management can deploy to preserve continuity and fund near-term strategic initiatives.
Bears Say
Zero Revenue And Heavy Cash BurnPersistent negative operating and free cash flow without commercial revenue creates a structural funding requirement. Continuous burn forces repeated external financing, raises dilution risk, constrains R&D prioritization, and undermines sustainable margin improvements until a product is commercialized or large contracts are secured.
Termination Of Phase 3 HyBryte ProgramHalting a Phase 3 program removes a late-stage value driver and wastes prior investment, materially reducing near-term clinical catalysts. This increases reliance on earlier-stage or alternative programs, lengthens time to potential revenue, and raises execution and partnering risk for future approvals or commercialization.
Nasdaq Minimum-bid Non-compliance RiskA formal non-compliance notice introduces listing risk that can restrict liquidity and investor access if unresolved. Delisting or prolonged compliance efforts raise cost of capital, deter institutional participation, and could materially hinder the company’s ability to raise equity efficiently—critical given ongoing cash burn.
Soligenix News
0A6I FAQ
What was Soligenix’s price range in the past 12 months?
Soligenix lowest share price was $0.28 and its highest was $6.20 in the past 12 months.
What is Soligenix’s market cap?
Soligenix’s market cap is $8.71M.
When is Soligenix’s upcoming earnings report date?
Soligenix’s upcoming earnings report date is Nov 06, 2026 which is in 82 days.
How were Soligenix’s earnings last quarter?
Soligenix released its earnings results on Aug 07, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.155 by $0.035.
Is Soligenix overvalued?
According to Wall Street analysts Soligenix’s price is currently Undervalued.
Does Soligenix pay dividends?
Soligenix does not currently pay dividends.
What is Soligenix’s EPS estimate?
Soligenix’s EPS estimate is -0.11.
How many shares outstanding does Soligenix have?
Soligenix has 21,765,478 shares outstanding.
What happened to Soligenix’s price movement after its last earnings report?
Soligenix reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.155. Following the earnings report the stock price went up 2.902%.
Which hedge fund is a major shareholder of Soligenix?
Currently, no hedge funds are holding shares in GB:0A6I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
0A6I Stock 12 Month Forecast
Average Price Target
$1.50
▲(305.41% Upside)